eBook: An Alzheimer’s drug, from discovery to approval
Aducanumab is a drug aimed at treating Alzheimer’s disease. The drug was approved for use by the US FDA in June 2021, a controversial decision that caused much debate within the neuroscience community. This eBook serves as a timeline for the drug, with content spanning the first aducanumab clinical trial in 2016, to expert opinions on the approval decision in 2021.
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
